Global Trial in APG2575 for Patients With CLL/SLL (NCT06104566)
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)
🩺 Plain-English Summary (8th-Grade Level)
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Who can join: Review the eligibility criteria below.
Location: Ascentage Investigative Site — Tuscon, Arizona
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (135 Sites)
Showing the first 25 of 135 sites.
- Ascentage Investigative Site — Tuscon, Arizona
- Ascentage Investigative Site — Anaheim, California
- Ascentage Investigative Site — Jacksonville, Florida
- Ascentage Investigative Site — Miami Beach, Florida
- Ascentage Investigative Site — Peoria, Illinois
- Ascentage Investigative Site — Boston, Massachusetts
- Ascentage Investigative Site — Ann Arbor, Michigan
- Ascentage Investigative Site — Greenville, North Carolina
- Ascentage Investigative Site — Houston, Texas
- Ascentage Investigative Site — Kingswood, Texas
- Ascentage Investigative Site — Richmond, Virginia
- Ascentage Investigative Site — Gosford,
- Ascentage Investigative Site — Perth,
- Ascentage Investigative Site — Westmead,
- Ascentage Investigative Site — Ghent,
- Ascentage Investigative Site — La Louvière,
- Ascentage Investigative Site — Leuven,
- Ascentage Investigative Site — Ottignies,
- Ascentage Investigative Site — Roeselare,
- Ascentage Investigative Site — Sofia,
- Ascentage Investigative Site — Sofia,
- Ascentage Investigative Site — Sofia,
- Ascentage Investigative Site — Sofia,
- Ascentage Investigative Site — Halifax, Nova Scotia
- Ascentage Investigative Site — Hefei, Anhui
📞 Contact the Study Coordinator
Phone: (301) 792-5062
Email: shanthi.marur@ascentage.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in CLL/SLL
- Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies — Duarte, California
- Study of Epcoritamab as a Consolidation Therapy in CLL/SLL — Cincinnati, Ohio
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. — Durham, North Carolina
- Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL — Duarte, California
Explore by condition: All CLL/SLL clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.